Home > News > 185/Plasminogen activator inhibitor-1 as a predictor of atrial fibrillation recurrence after radiofrequency catheter ablation of pulmonary veins
Atrial Fibrillation, Devices, Interventional Cardiology
Read Time: < 1 min

185/Plasminogen activator inhibitor-1 as a predictor of atrial fibrillation recurrence after radiofrequency catheter ablation of pulmonary veins

Published Online: October 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr185
Authors: R Rekvava (Presenting Author) – Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan; N Bregvadze-Tabagari – Davit Tvildiani Medical University, Tbilisi, Georgia; Z Pagava – The center of vascular and heart disease, Tbilisi, Georgia; S Berkinbayev – Kazakh National Medical University named after S.Asfendiyarov, Almaty, Kazakhstan; G Dussekeyeva – Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan; R Kuanyshbekova – Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
Quick Links:
Article
Article Information
Article:

Background and aim of the study: Recurrence of atrial fibrillation (AF) after radiofrequency ablation (RFA) of pulmonary veins is still an ongoing problem and its predictors have not been fully determined. Aim of this study was to identify whether Plasminogen Activator Inhibitor 1 (PAI-1) can predict the development of post-ablation AF recurrence.

Methods: We enrolled 75 adult patients undergoing RFA of pulmonary vein for AF, who had sinus rhythm within 3 months after ablation. Follow-up data were assessed and plasma PAI-1 levels were measured at 3, 6, 9 and 12 months after RFA.

Results: Patients who developed recurrence of AF after ablation (16 subjects, 21.3%) more likely to have a remote history of AF (p<0.001). PAI-1 levels in the blood were significantly higher in patients who have developed post-ablation AF than in patients with SR after ablation (p=0.012). Logistic regression identified the remote history of AF (p=0.001) and post-ablation PAI-1 levels (p=0.022) as independent predictors of post-ablation AF. The Chi-squared automatic interaction detection (CHAID) model indicated that post-ablation PAI-1 antigen level determined risk of AF (12.5% for PAI-1 ≤28.5 ng/mL versus 45.3% for PAI-1 >28.5 ng/mL).

Conclusion: An elevated PAI-1 antigen levels after RFA of pulmonary vein for atrial fibrillation could be an independent predictor for development of post-ablation AF. Further investigations are needed to determine whether drugs that reduce PAI-1 concentrations can also reduce the risk of post-ablation AF.

Article Information:

Further Resources

Share this Article
Related Content In Interventional Cardiology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72